Contineum Therapeutics, Inc. (CTNM)
13.04
+1.54
(+13.35%)
USD |
NASDAQ |
Sep 30, 11:01
Contineum Therapeutics Enterprise Value : 202.58M for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 202.58M |
| September 28, 2026 | 248.84M |
| September 25, 2026 | 242.45M |
| September 24, 2026 | 239.81M |
| September 23, 2026 | 240.57M |
| September 22, 2026 | 274.04M |
| September 21, 2026 | 279.68M |
| September 18, 2026 | 278.93M |
| September 17, 2026 | 266.90M |
| September 16, 2026 | 287.58M |
| September 15, 2026 | 289.84M |
| September 14, 2026 | 327.45M |
| September 11, 2026 | 327.45M |
| September 10, 2026 | 321.44M |
| September 09, 2026 | 339.49M |
| September 08, 2026 | 369.58M |
| September 04, 2026 | 398.17M |
| September 03, 2026 | 430.89M |
| September 02, 2026 | 418.48M |
| September 01, 2026 | 392.52M |
| August 31, 2026 | 380.86M |
| August 28, 2026 | 411.33M |
| August 27, 2026 | 418.85M |
| August 26, 2026 | 410.20M |
| August 25, 2026 | 411.33M |
| Date | Value |
|---|---|
| August 24, 2026 | 395.53M |
| August 21, 2026 | 416.60M |
| August 20, 2026 | 372.59M |
| August 19, 2026 | 372.59M |
| August 18, 2026 | 315.42M |
| August 17, 2026 | 316.55M |
| August 14, 2026 | 303.76M |
| August 13, 2026 | 345.51M |
| August 12, 2026 | 333.47M |
| August 11, 2026 | 327.45M |
| August 10, 2026 | 315.04M |
| August 07, 2026 | 335.73M |
| August 06, 2026 | 347.39M |
| August 05, 2026 | 344.38M |
| August 04, 2026 | 368.08M |
| August 03, 2026 | 369.20M |
| July 31, 2026 | 352.65M |
| July 30, 2026 | 362.43M |
| July 29, 2026 | 310.90M |
| July 28, 2026 | 302.63M |
| July 27, 2026 | 291.34M |
| July 24, 2026 | 298.87M |
| July 23, 2026 | 310.53M |
| July 22, 2026 | 324.07M |
| July 21, 2026 | 292.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.54M |
| CNBX Pharmaceuticals, Inc. | 1.379M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -69.95M |
| Fulcrum Therapeutics, Inc. | -31.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.15M |
| Total Expenses (Quarterly) | 15.15M |
| EPS Diluted (Quarterly) | -0.4044 |
| Earnings Yield | -13.33% |
| Normalized Earnings Yield | -13.33 |